The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD) Meeting Abstract
| Authors: | Chowdhury, S.; Abida, W.; Arija, J. A.; Daugaard, G.; Fizazi, K.; Gez, E.; Heidenreich, A.; Joly Lobbedez, F.; McDermott, R.; Merseburger, A. S.; Piulats Rodriguez, J. M.; Sautois, B.; Sridhar, S.; Sternberg, C. N.; Watkins, S.; Simmons, A.; Shetty, S.; Golsorkhi, A.; Ryan, C. J.; Scher, H. |
| Abstract Title: | The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD) |
| Meeting Title: | 42nd ESMO Congress (ESMO 2017) |
| Journal Title: | Annals of Oncology |
| Volume: | 28 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2017 Sep 8-12 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2017-09-01 |
| Start Page: | v291 |
| Language: | English |
| ACCESSION: | WOS:000411324002027 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdx370.053 |
| Notes: | Meeting Abstract: 836TiP -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
